Skip to main content

Sodium acetate anhydrous

Generic: Sodium acetate anhydrous

Verified·Apr 23, 2026
Manufacturer
American Regent
NDC
70069-047
RxCUI
237371
Route
INTRAVENOUS
ICD-10 indication
E87.1

Affordability Check

How much will you actually pay for Sodium acetate anhydrous?

In 30 seconds, see every legitimate way to afford Sodium acetate anhydrous — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About Sodium acetate anhydrous

What is this medication? Sodium acetate anhydrous is an electrolyte replenisher primarily used as an additive for intravenous fluids, specifically in total parenteral nutrition. It serves as a concentrated source of sodium for patients who are unable to consume adequate nutrition orally or have specific medical requirements for electrolyte balance. By providing sodium ions, it helps maintain the necessary osmotic pressure and fluid balance within the body's extracellular fluid compartments.

In addition to its role as a sodium source, this medication is frequently utilized as an alkalinizing agent to help correct metabolic acidosis. Once it enters the bloodstream, the acetate ions are metabolized into bicarbonate, which helps increase the pH of the blood and reduce overall acidity. This makes it a valuable component for managing patients with clinical conditions that lead to bicarbonate loss or other severe acid-base imbalances during hospital care.

Copay & patient assistance

Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program for more details.

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Prescribing information

From the FDA-approved label for Sodium acetate anhydrous. Official source: DailyMed (NLM) · Label effective Oct 21, 2025

Boxed warning
Pharmacy Bulk Package. Not for Direct Infusion
Indications and usage
INDICATIONS AND USAGE Sodium acetate injection (2 mEq/mL) is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions.
Dosage and administration
DOSAGE AND ADMINISTRATION Sodium acetate injection (2 mEq/mL) is administered intravenously only after dilution in a larger volume of fluid . The dose and rate of administration are dependent upon the individual needs of the patient. Serum sodium should be monitored as a guide to dosage. Using aseptic technique, transfer the desired amount to other intravenous fluids to provide the appropriate number of milliequivalents (mEq) of sodium acetate. Sodium acetate injection (2 mEq/mL) in the pharmacy bulk package is designed for use with manual, gravity flow operations and automated compounding devices for preparing intravenous nutritional admixtures. Admixtures must be stored under refrigeration and used within 24 hours after compounding. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration (See PRECAUTIONS ). Directions for Dispensing From Pharmacy Bulk Package The pharmacy bulk package is for use in the pharmacy admixtures service only. For hanger application, peel off the paper liner from both ends of the tape hanger to expose ¾ inch long adhesive portions. Adhere each end to the label on the bottle. The vials should be suspended as a unit in the laminar flow hood. A single entry through the vial closure should be made with a sterile dispensing set or transfer device. Transfer individual doses to appropriate intravenous infusion solutions. Use of a syringe with needle is not recommended as it may cause leakage and multiple entries will increase the potential of microbial and particulate contamination. The above process should be carried out under a laminar flow hood using aseptic technique. Discard any unused portion within 4 hours after initial closure entry.
Contraindications
CONTRAINDICATIONS Sodium acetate injection (2 mEq/mL) is contraindicated in patients with hypernatremia or fluid retention.
Warnings
WARNINGS Sodium acetate injection (2 mEq/mL) must be diluted before use. To avoid sodium overload and water retention, infuse sodium-containing solutions slowly. Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention. In patients with diminished renal function, administration of solutions containing sodium ions may result in sodium retention. Solutions containing acetate ions should be used with great care in patients with metabolic or respiratory alkalosis. Acetate should be administered with great care in those conditions in which there is an increased level or an impaired utilization of this ion, such as severe hepatic insufficiency. The intravenous administration of this solution (after appropriate dilution) can cause fluid and/or solute overloading resulting in dilution of other serum electrolyte concentrations, overhydration, congested states or pulmonary edema. Excessive administration of potassium free solutions may result in significant hypokalemia. WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
Adverse reactions
ADVERSE REACTIONS Sodium overload can occur with intravenous infusion of excessive amounts of sodium-containing solutions (See WARNINGS and PRECAUTIONS ).

Label text is reproduced as-is from the FDA-approved label. We do not paraphrase, summarize, or omit. Content above is for informational purposes only and is not medical advice. Always consult your prescribing clinician or pharmacist before making decisions about your medication.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Prior authorization & coverage

PayerPAStep therapyCopay tier

Medicare Part D

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.